BIMEKIZUMAB
Information current as at: 1 October 2024
The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.
Submission Details
- Brand name:
-
- Bimzelx®
- Pharmaceutical company:
- UCB Australia Proprietary Limited
- Condition/indication:
(therapeutic use) -
- Plaque psoriasis
- PBAC Submission type:
- New listing (–)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – March 2022
- Related medicines:
- --
Progress Details
-
Submission received for: - March 2022 PBAC meeting
-
Opportunity for consumer comment: - Open 24/11/2021 and close 27/01/2022 (see PBS Website)
-
PBAC meeting: - Held on 09/03/2022
-
PBAC outcome published: - Recommended (see PBAC Outcomes)
-
Notice of intent submitted:
- Awaiting lodgement from pharmaceutical company
-
5Lodgement of required documentation:
- Has not yet commenced
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
Case ID: a457
Page last updated: 02 May 2024